Skip to main content

Table 1 Demographic characteristics of the whole cohort and subgroups before and after weighted propensity score analysis

From: Impact of a restrictive antibiotic policy on the acquisition of extended-spectrum beta-lactamase-producing Enterobacteriaceae in an endemic region: a before-and-after, propensity-matched cohort study in a Caribbean intensive care unit

Whole cohort

Before weighted PPS analysis

p value

After weighted PPS analysis

p value

Conventional strategy period 2014

Restrictive strategy period 2015

Conventional strategy period 2014

Restrictive strategy period 2015

n = 738

n = 803

n = 1539.427

n = 1541.373

Age, years, mean (± SD)

56.21 (18.49)

55.40 (19.32)

0.53

55.63 (18.67)

55.7 (19.25)

0.924

SAPS II, mean (± SD)

42.2 (21.08)

39.57 (22.03)

 < 0.01

40.71 (20.90)

40.78 (22.2)

0.928

Diabetes

220 (29.8)

207 (25.8)

 < 0.01

424.923 (27.6)

427.796 (27.8)

0.925

Chronic renal insufficiency

78 (10.6)

102 (12.7)

0.19

173.641 (11.3)

177.866 (11.5)

0.821

Immunosuppression

48 (6.5)

89 (11.1)

 < 0.01

133.373 (8.7)

136.391 (8.8)

0.856

Antibiotherapy in the last 3 months

288 (39.0)

304 (37.9)

0.64

593.102 (38.5)

593.741 (38.5)

0.997

MDR bacteria carrier at ICU admission a

51 (6.9)

68 (8.5)

0.25

116.09 (7.5)

118.888 (7.7)

0.857

Sepsis (at ICU admission or acquired during ICU stay)

380 (51.5)

327 (40.7)

 < 0.001

706.351 (45.9)

706.214 (45.8)

0.970

Invasive mechanical ventilation > 48 h

438 (59.3)

364 (45.3)

 < 0.001

802.415 (52.1)

802.174 (52.0)

0.964

Subgroup of antibiotherapy

n = 427

n = 376

 

n = 802.348

n = 803.804

 

Age, years, mean (± SD)

57.24 (17.53)

56.11 (18.93)

0.538

56.55 (17.63)

56.65 (18.80)

0.908

SAPS II, mean (± SD)

44.94 (21.12)

44.51 (22.54)

0.688

44.40 (21.63)

44.49 (22.22)

0.935

Diabetes

136 (31.9)

95 (25.3)

0.04

233.098 (29.1)

235.304 (29.3)

0.922

Chronic renal insufficiency

51 (11.9)

48 (12.8)

0.724

96.529 (12.0)

98.767 (12.3)

0.876

Immunosuppression

32 (7.5)

53 (14.1)

 < 0.01

84.614 (10.5)

84.99 (10.6)

0.985

Antibiotherapy in the last 3 months

242 (56.7)

230 (61.2)

0.197

472.742 (58.9)

474.143 (59.0)

0.978

MDR bacteria carrier at ICU admission a

42 (9.8)

46 (12.2)

0.278

85.660 (10.7)

87.590 (10.9)

0.867

Sepsis (at ICU admission or acquired during ICU stay)

372 (87.1)

315 (83.8)

0.179

685.882 (85.5)

687.384 (85.5)

0.986

Invasive mechanical ventilation > 48 h

309 (72.4)

228 (60.6)

 < 0.001

535.210 (66.7)

536.928 (66.8)

0.969

Subgroup of septic shock

n = 172

n = 156

 

n = 325.179

n = 329.259

 

Age, years, mean (± SD)

60.88 (13.85)

62.91 (14.44)

0.183

61.77 (13.36)

61.92 (14.93)

0.892

SAPS II, mean (± SD)

54.69 (22.19)

54.22 (22.77)

0.980

54.73 (22.59)

54.48 (22.80)

0.884

Diabetes

64 (37.2)

48 (30.8)

0.219

113.156 (34.8)

115.746 (35.2)

0.924

Chronic renal insufficiency

24 (14.0)

24 (15.4)

0.714

48.133 (14.8)

51.222 (15.6)

0.788

Immunosuppression

17 (9.9)

31 (19.9)

0.011

46.225 (14.2)

47.780 (14.5)

0.914

Antibiotherapy in the last 3 months

95 (55.2)

111 (71.2)

0.003

200.219 (61.6)

205.274 (62.3)

0.839

MDR bacteria carrier at ICU admission a

15 (8.7)

31 (19.9)

0.004

41.819 (12.9)

45.429 (13.8)

0.724

Invasive mechanical ventilation > 48 h

149 (86.6)

108 (69.2)

 < 0.001

257.203 (79.1)

258.344 (78.5)

0.843

  1. When not specified, results are n (%).
  2. PPS propensity score, SAPS II Simplified Acute Physiology Score II; MRSA methicillin-resistant Staphylococcus aureus, ESBL-E: Extended-spectrum beta-lactamase-producing Enterobacteriaceae, MDR multidrug resistant, SD standard deviation.
  3. aMultidrug-resistant bacteria including ESBL-E and MRSA.